UQAM awards an honorary doctorate to Dr. Réjean Thomas
Montreal becomes the first Canadian city to commit to eradicating HIV by 2030, in collaboration with l'Actuel Clinic
L'Actuel goes to the Museum with Mapplethorpe
L'Actuel offers PrEP Clinics
New Gynecologist in Montreal
Dr. Réjean Thomas is named Great Montrealer
Prix du mérite 2014
Cured of hepatitis C
2014 Hippocrate Award:
[Video] AIDS International Conference 2014
The Claude-Tourangeau Award
Conference: Prevention in 2014
Hepatitis C: Breakthrough
Breakthrough New Treatments for Hep C
HIV and AIDS: changing terminology
Incubation Periods for STI's (STD's)
New STI - STD - named MG
L'Actuel endorse CQ-LGBT's position
LGV Outbreak in Montreal
H041 - Superbug
HIV and Aging
ALERT — Hep C
LGV OUTBREAK
HIV — Treating children is challenging
Testimony
MotsEcho.com
World AIDS Day – December 1, 2012
Gonorrhea and chlamydia
INSPQ Report on STIs and STBBIs in Québec
People living with HIV/aids New Survey
Our Team at IUSTI Conference in Melbourne, Australia
[Advisory] Selling of Unlicensed Home-Use HIV and STDs Test Kits
[Interview] 25% of people infected by HIV do not know it
Gay Pride — August 18, 2012
Dr. Réjean Thomas' Op-Ed - Montreal Pride Week -- August 2012
HIV Prophylaxis for Heterosexuals: Conflicting Trial Results
WHO Worries About Gonorrhea
NIH scientists identify new HIV-inhibiting protein
About PREP (Truvada®)
Dr Réjean Thomas, Editor of the day in Métro newspaper
Increase of the infectious syphilis in young people
INCIVEK™ (telaprevir)
Syphilis in women in Quebec
Réjean Thomas on Radio-Canada
La Clinique A rue McGill invited to Une pilule, une petite granule
HIV/Aids in Progress with Young Adults
NYC Recommends AIDS Drugs For Any Person With HIV
« Petite révolution » dans le traitement de l'hépatite C
Ban Ki-Moon wants to eradicate AIDS in the next 10 years...s….

UQAM awards an honorary doctorate to Dr. Réjean Thomas Montreal becomes the first Canadian city to commit to eradicating HIV by 2030, in collaboration with l'Actuel Clinic L'Actuel goes to the Museum with Mapplethorpe L'Actuel offers PrEP Clinics New Gynecologist in Montreal Dr. Réjean Thomas is named Great Montrealer Prix du mérite 2014 Cured of hepatitis C 2014 Hippocrate Award: [Video] AIDS International Conference 2014 The Claude-Tourangeau Award Conference: Prevention in 2014 Hepatitis C: Breakthrough Breakthrough New Treatments for Hep C HIV and AIDS: changing terminology Incubation Periods for STI's (STD's) New STI - STD - named MG L'Actuel endorse CQ-LGBT's position LGV Outbreak in Montreal H041 - Superbug HIV and Aging ALERT — Hep C LGV OUTBREAK HIV — Treating children is challenging Testimony MotsEcho.com World AIDS Day – December 1, 2012 Gonorrhea and chlamydia INSPQ Report on STIs and STBBIs in Québec People living with HIV/aids New Survey Our Team at IUSTI Conference in Melbourne, Australia [Advisory] Selling of Unlicensed Home-Use HIV and STDs Test Kits [Interview] 25% of people infected by HIV do not know it Gay Pride — August 18, 2012 Dr. Réjean Thomas' Op-Ed - Montreal Pride Week -- August 2012 HIV Prophylaxis for Heterosexuals: Conflicting Trial Results WHO Worries About Gonorrhea NIH scientists identify new HIV-inhibiting protein About PREP (Truvada®) Dr Réjean Thomas, Editor of the day in Métro newspaper Increase of the infectious syphilis in young people INCIVEK™ (telaprevir) Syphilis in women in Quebec Réjean Thomas on Radio-Canada La Clinique A rue McGill invited to Une pilule, une petite granule HIV/Aids in Progress with Young Adults NYC Recommends AIDS Drugs For Any Person With HIV « Petite révolution » dans le traitement de l'hépatite C Ban Ki-Moon wants to eradicate AIDS in the next 10 years...s….

INCIVEK™ (telaprevir)

April 25 2012

"LAVAL, Quebec--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated announced today that the province of Quebec is now funding INCIVEK™ (telaprevir) tablets for residents living with chronic hepatitis C. The decision comes following a priority evaluation by the Institut National d'Excellence en Santé et en Services Sociaux (INESSS). This decision includes funding for patients who are being treated for the first time as well as those who were treated previously, but did not achieve a sustained virologic response (SVR, or virologic cure), including null responders. (...)"

Read complete press release